Differences in proinflammatory activity of several immunomodulatory derivatives of muramyl dipeptide (MDP) with special reference to the mechanism of the MDP effects

. 1992 May ; 36 (1-2) : 136-45.

Jazyk angličtina Země Švýcarsko Médium print

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid01414682

Immunomodulatory agents, muramyl dipeptide (MDP) and several of its analogues, i.e. adamantylamide dipeptide, murametide, murabutide and their glucosaminylated derivatives, were tested for edemagenic activity in rats. Given systemically in aqueous solutions, only MDP and glucosaminylated MDP, at the dose of 3 mg/kg (s.c. or p.o.), were found to produce edematous swelling of the paws. Local (intra-pad) application of MDP was more effective than the systemic one. Supernatants of macrophages, in vitro cultured in presence of MDP, caused the swelling as well. The edema was of a transient nature. After reaching the maximum severity (about 6 h after injection of MDP solution or 1 h after macrophage supernatants), it was subsiding and disappeared completely within approximately 6 days after cessation of the treatment. It was found that this type of rat paw edema is probably a prostaglandin-dependent consequence of macrophage activation. Hypotheses on the involvement of immunoregulatory cytokines, and possible chemical structure-inflammatory activity relationships have been suggested.

Zobrazit více v PubMed

Methods Find Exp Clin Pharmacol. 1985 Aug;7(8):419-26 PubMed

J Infect Dis. 1980 Nov;142(5):708-15 PubMed

Int J Immunopharmacol. 1979;1(1):35-41 PubMed

Am J Physiol. 1984 Sep;247(3 Pt 1):C169-74 PubMed

Infect Immun. 1982 Feb;35(2):417-24 PubMed

J Immunol. 1988 May 1;140(9):3021-5 PubMed

Proc Natl Acad Sci U S A. 1987 Jun;84(12):4273-7 PubMed

Clin Immunol Immunopathol. 1989 Dec;53(3):488-98 PubMed

J Exp Med. 1981 Apr 1;153(4):1021-6 PubMed

Eur J Immunol. 1984 Oct;14(10):898-901 PubMed

Int J Immunopharmacol. 1982;4(5):451-62 PubMed

Ryumachi. 1981;21 Suppl:149-56 PubMed

Infect Immun. 1981 Feb;31(2):758-66 PubMed

J Clin Invest. 1988 May;81(5):1384-9 PubMed

J Clin Invest. 1986 Mar;77(3):1020-7 PubMed

J Exp Med. 1986 Jun 1;163(6):1433-50 PubMed

Eur J Immunol. 1988 Jun;18(6):957-9 PubMed

Infect Immun. 1986 Sep;53(3):511-6 PubMed

Agents Actions. 1989 Jan;26(1-2):186-8 PubMed

Infect Immun. 1980 Jul;29(1):70-5 PubMed

FASEB J. 1989 Dec;3(14):2565-73 PubMed

Infect Immun. 1982 Feb;35(2):674-9 PubMed

Annu Rev Immunol. 1984;2:335-57 PubMed

J Immunol. 1990 Mar 15;144(6):2223-32 PubMed

Science. 1989 Feb 24;243(4894 Pt 1):1066-8 PubMed

N Engl J Med. 1983 Mar 10;308(10):553-8 PubMed

Infect Immun. 1980 May;28(2):624-6 PubMed

Infect Immun. 1986 Sep;53(3):517-21 PubMed

Proc Natl Acad Sci U S A. 1976 Jul;73(7):2472-5 PubMed

Microbiol Immunol. 1986;30(7):717-23 PubMed

Methods Find Exp Clin Pharmacol. 1984 Nov;6(11):667-9 PubMed

Science. 1986 Oct 24;234(4775):470-4 PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...